

March 28, 2023

**BSE Limited**  
P.J. Towers, Dalal Street, Fort,  
Mumbai 400 001  
**BSE scrip code:** 543635

**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400 051  
**NSE symbol:** PPLPHARMA

**Sub: Proposed issue of equity shares on a rights basis to the eligible equity shareholders by Piramal Pharma Limited (“Company”)**

Dear Sir/Madam,

Kindly refer to our letter dated February 8, 2023 whereby we had informed that the board of directors of the Company (the “**Board**”) had, *inter alia*, approved the issuance of fully paid-up equity shares of the Company by way of a rights issue to the existing shareholders of the Company for an amount not exceeding ₹ 1,050 crores (“**Issue**”).

Pursuant to the above referred approval, we wish to inform that the Company has on March 28, 2023, filed the draft letter of offer in connection with the Issue with the Securities and Exchange Board of India, BSE Limited and the National Stock Exchange of India Limited.

This intimation is issued in terms of Regulation 30 of the SEBI Listing Regulations.

You are requested to kindly take the same on record.

**For Piramal Pharma Limited**

**Tanya Sanish**  
Company Secretary

**Piramal Pharma Limited**

CIN: U24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India

T +91 22 3802 3000 / 4000

[piramal.com](http://piramal.com)